Racial differences in lipid-lowering agent use in medicaid patients with cardiovascular disease

Medical Care
David Litaker, Siran M Koroukian

Abstract

Racial differences in chronic cardiovascular disease (CVD) outcomes are well described, whereas less is known about the process of CVD preventive care and its potential contribution to disparate outcomes. The objective of this study was to examine the association between race and 1) prior use of a lipid-lowering agent (LLA), 2) LLA initiation, and 3) LLA discontinuation among individuals with an incident medical claim for CVD. Retrospective claims analysis. We studied continuously enrolled, fee-for-service Medicaid recipients <65 with a new medical claim for 1 of 15 CVD-related diagnoses or procedures from 1993 to 1998 (n = 14,833). Pharmacy claims history reflecting previous, new, and ongoing LLA use were reviewed for the 24-month period around a new CVD claim. Multivariable logistic regression assessed the independent effect of minority status on new and ongoing LLA use controlling for clinical and demographic characteristics. A total of 3924 (26.4%) individuals submitted LLA pharmacy claims. A total of 3668 of 4668 (78.6%) previous or new users obtained > or =1 refill. Minorities were less likely to have previously used LLA (adjusted odds ratio [AOR], 0.64; 95% confidence interval [CI], 0.58-0.70), to receive a new prescript...Continue Reading

References

Jun 1, 1992·Journal of Clinical Epidemiology·R A DeyoM A Ciol
Nov 1, 1991·Journal of the American Geriatrics Society·R E Johnson, W M Vollmer
Apr 1, 1989·American Journal of Epidemiology·W A Ray, M R Griffin
Sep 1, 1986·Preventive Medicine·P A Nutting
Jan 8, 1996·Archives of Internal Medicine·C J NewschafferM Whittemore
Jun 1, 1996·The American Journal of Medicine·J J Marcelino, K R Feingold
Dec 1, 1996·Journal of Health and Social Behavior·C M Brown, R Segal
Jan 1, 1997·Journal of Clinical Epidemiology·J F Steiner, A V Prochazka
May 1, 1997·Journal of General Internal Medicine·J WhittleM Joswiak
Jun 6, 1998·BMJ : British Medical Journal·E DelacrétazB Meier
May 26, 1998·JAMA : the Journal of the American Medical Association·J AvornJ LeLorier
Jul 17, 1998·Archives of Internal Medicine·J A FergusonW M Tierney
Feb 25, 1999·The New England Journal of Medicine·K A SchulmanJ J Escarce
Apr 8, 1993·Journal of Aging and Health·M BazarganV Hamm
Apr 30, 1999·Pharmacotherapy·J A KotzanW E Wade
Aug 18, 1999·JAMA : the Journal of the American Medical Association·L Cooper-PatrickD E Ford
Oct 26, 1999·Journal of Developmental and Behavioral Pediatrics : JDBP·C E IeversR G Lambert
Jan 29, 2000·Cancer·K S OgleF Azzouz
Feb 9, 2000·Archives of Pediatrics & Adolescent Medicine·D MatsuiM J Rieder
May 12, 2000·The American Journal of Medicine·S S RathoreK A Schulman
Sep 13, 2000·American Journal of Public Health·N DuanS Carson
Nov 25, 2000·Medical Care Research and Review : MCRR·L C Einbinder, K A Schulman
Mar 10, 2001·JAMA : the Journal of the American Medical Association·U StenestrandUNKNOWN Swedish Register of Cardiac Intensive Care (RIKS-HIA)
Jan 10, 2002·Journal of Clinical Epidemiology·Isabelle Savoie, Arminée Kazanjian

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.